February 26, 2024
Safety and Efficacy of Eblasakimab in Moderate-to-Severe Atopic Dermatitis
Eblasakimab is efficacious and well-tolerated for treating adults with moderate-to-severe atopic dermatitis, according to a recent cohort study. Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease. Despite advances in systemic therapies for moderate-to-severe AD, therapeutic options remain limited. Eblasakimab is a novel human monoclonal antibody that binds the interleukin (IL)-13 receptor α1...
Psoriasis Severity Assessment Based on Artificial Intelligence
by Deileta Kamhunga An artificial intelligence-based psoriasis severity assessment model may be a promising alternative for dermatologists’ assessments, according to a real-world study. Psoriasis is a chronic, immune-mediated skin disease. The therapeutic management plan for psoriasis is established according to the degree of disease severity. The Psoriasis Area and Severity Index (PASI) is currently the...
Comparison of Candidate Biosimilar CT-P43 to Originator Ustekinumab in Plaque Psoriasis
CT-P43 demonstrated efficacy and safety comparable to originator ustekinumab in treating moderate-to-severe plaque psoriasis in a phase III trial. Plaque psoriasis is a chronic inflammatory disease with an estimated prevalence of ≥1.5% in Australasia, Western and Central Europe, and North America. Ustekinumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. A randomized, active-controlled,...
Stage I Endometrial Cancer Post-Surgical Circulating Tumor DNA Levels: Patient Outcomes
by Deileta Kamhunga Post-surgical circulating tumor DNA detection is predictive of poor recurrence-free survival in stage I endometrial cancer patients, according to a recent retrospective analysis. Endometrial cancer (EC) is the most common gynecologic malignancy of the female reproductive tract. Circulating tumor DNA (ctDNA), a blood-based biomarker, predicts disease outcomes and detects molecular relapse ahead...
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Solid Tumors
Trastuzumab deruxtecan shows robust efficacy, durable clinical benefit, and safety consistent with the known profile in human epidermal growth factor receptor 2-expressing tumors in a phase II study. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, is currently approved for treating HER2-expressing breast and gastric cancers and HER2-mutant non-small cell...